Anti-CD40-7409 is under clinical development by Protheragen and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anti-CD40-7409’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Anti-CD40-7409 overview

The therapeutic candidate is under development for the treatment of solid tumors, head and neck squamous cell carcinomas (HNSCC), non-small cell lung cancer (NSCLC), esophagogastric-junction cancer (EGJC), and hepatocellular carcinoma (HCC). It is a humanized IgG monoclonal antibody with an engineered Fc that selectively binds to Fc gamma receptor IIB (Fc gamma RIIB). It acts by targeting cells expressing CD40.

Protheragen overview

Protheragen (Protheragen) discovers and develops therapies to treat cancers. The company is investing CD3XCD20 bsAb, an antibody therapy for the treatment of lymphomas; MUC1-Ab targeting acute myelocytic leukemia; LAG3-Ab and OX40-Ab to treat cancers; P75NEURO, against neurological diseases; P11 for the treatment of type 2 diabetes; and TT-173 against surgical bleeding and trauma. It is also developing therapies to treat nonalcoholic steatohepatitis, hepatitis B, epilepsy, Alzheimer’s disease and Psoriasis. Protheragen’s proprietary cyclic peptide information technology enables discovery of peptide therapeutics. The company provides project collection, transfer, collaboration and fundraising services. It operates in China. Protheragen is headquartered in New York, the US.

For a complete picture of Anti-CD40-7409’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.